Edgewise Therapeutics, Inc. · NASDAQ:EWTX

Edgewise Therapeutics — Technical Presentation (November 2026)

9 slides from Edgewise Therapeutics's technical presentation, November 2026

  1. Slide 1: EDG-15400 Prevents Development of Diastolic Dysfunction in ZSF1 Rat HFpEF Model

    EDG-15400, A NOVEL SARCOMERE MODULATOR, PREVENTS THE DEVELOPMENT OF DIASTOLIC DYSFUNCTION IN THE ZSF1 RAT MODEL OF HEART FAILURE WITH PRESERVED EJECTION FRACTION Marcus Henze1, Yangsong Wu 1, Amy Perry1, Kayla Wald1, Sarah Larkin 1, Craig Emter1, Alan J Russell1 1Edgewise Therapeutics, Boulder, CO,

  2. Slide 2: Disclosure Slide

    DISCLOSURE SLIDE Craig A. Emter, PhD, is an employee of Edgewise Therapeutics, EDG-15400 is an investigational agent that is not approved for use by any regulatory authority in any territory and its safety and efficacy have not been established. 2

  3. Slide 3: ZSF1 Rats Develop Symptoms Consistent with Comorbidities of HFpEF

    ZSF1 RATS DEVELOP SYMPTOMS CONSISTENT WITH COMORBIDITIES OF HFpEF WITH DIASTOLIC IMPAIRMENT 300 150 Blood Glucose (mg/dL) 800 25 30 ** *** ** *** *** MBP (mmHg) 20 200 100 600 *** * *** *** 20 IVRT (ms) BW (g) 15 E/e' 400 100 50 10 10 200 5 0 0 0 0 0 h eh h eh Ve -V Ve -V 10 15 20 25 10 15 20 25 10

  4. Slide 4: Study Design: A Preclinical Model of HFpEF

    STUDY DESIGN : A PRECLINICAL MODEL OF HFpEF WKY – Vehicle (n=8) WKY WKY – EDG-15400 (n=8) ZSF1 – Vehicle (n=8) ZSF1 ZSF1 – EDG-15400 (n=8) Baseline 4 weeks 10 weeks Echocardiography Study Aim: To determine if 10-weeks of daily oral administration of EDG-15400 can prevent the development of impaired

  5. Slide 5: EDG-15400: Limited and Transient Systolic Excursions

    EDG-15400: LIMITED AND TRANSIENT SYSTOLIC EXCURSIONS ✱ ns 1200 60 60 1000 50 50 [Plasma] (ng/mL) 800 40 40 2hr post dose FS (%) FS (%) 600 30 30 400 20 20 200 10 10 24h post dose 0 0 0 0 20 40 60 ZSF1 ZSF1 ZSF1 ZSF1 Days Veh 15400 Veh 15400 2 hours 24 hours post-dose post-dose Plasma exposures in WK

  6. Slide 6: Diastolic Function: Improved with EDG-15400 in ZSF1 Rats

    DIASTOLIC FUNCTION: IMPROVED WITH EDG-15400 IN ZSF1 RATS 1500 120 25 ** ** ** ** 100 20 1000 80 e' (mm/s) E (mm/s) 15 E/e' 60 10 500 40 20 5 0 0 0 0 5 10 0 5 10 0 5 10 Weeks Weeks Weeks No Change in Preserved Prevents pathological early filling mitral annular increase in LV filling velocity (E) velo

  7. Slide 7: EDG-15400 Improves Relaxation and Attenuates Increases in Left Atrial Size

    EDG-15400 IMPROVES RELAXATION AND ATTENUATES PATHOLOGICAL INCREASES IN LEFT ATRIAL SIZE IN ZSF1 RATS 30 30 *** *** *** ** LAmax Area (mm2) 25 IVRT (ms) 20 20 10 15 0 10 0 5 10 0 5 10 Weeks Weeks Prevents pathological Prevents increase in isovolumic pathological left relaxation time (IVRT). atrial en

  8. Slide 8: Conclusions: EDG-15400 Prevents Development of Diastolic Dysfunction

    EDG-15400, A NOVEL SARCOMERE MODULATOR, PREVENTS THE DEVELOPMENT OF DIASTOLIC DYSFUNCTION IN THE ZSF1 RAT MODEL OF HEART FAILURE WITH PRESERVED EJECTION FRACTION 1 2 Ten weeks of daily EDG-15400 treatment prevents the This is evident by signatures of improved early continuing development of diastoli

  9. Slide 9: Thank You

    THANK YOU #ScientificSessions26

Edgewise Therapeutics — Technical Presentation (November 2026) on 6ix